CytomX Reports Q3 2026 Results, Provides Business Update
CytomX said varsetatug masetecan received FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer. Phase 1 monotherapy data are expected in January 2027, and a combination study with bevacizumab is ongoing.
Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer -- Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 -- Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1…